{'fraction_non_alphanumeric': 0.03130434782608696, 'fraction_numerical': 0.0034782608695652175, 'mean_word_length': 6.024390243902439, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cytosine deaminase‐producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model

Background and Aim:  Stem cell transplantation offers potential gene therapy for brain tumors. However, this approach has received little attention as a treatment for gastrointestinal tumors. In the present study, we explored the possibility of human bone marrow‐derived mesenchymal stem cells (hMSC) producing cytosine deaminase (CD), followed by systemic 5‐fluorocytosine (5‐FC) administration, showing an antitumor effect on a mouse gastric cancer xenograft.